The first ever production facility dedicated to the manufacture
of surface enhanced Raman spectroscopy (SERS) substrates has opened
in Southampton, UK. The facility, which is a 1/4 million investment
by Mesophotonics Ltd., has been built in response to customer demand
for the companys Klarite substrates launched earlier this year.
One million times more effective than traditional lab-generated Raman
substrates, Klarite offers very high levels of sensitivity, reliability
and reproducibility and is already being used in more than 150 academic
and industrial laboratories worldwide.
Klarite signifies a major step forward in Raman spectroscopy,
explains Professor Michael Morris at the University of, who is using
Klarite in his SERS-based research on early identification of biomarkers
for osteoarthritis. It can finally become the pioneering analytical
tool that it promised to be when first developed thirty years ago.
As well as its role in medical research, specifically drug discovery
and production, Klarites ability to enable faster, higher accuracy
analysis of biological and chemical samples at lower detection limits
also makes it ideal for applications in forensics and homeland security.
We are delighted that Klarite has already had such a significant impact,
comments James McKenzie, CEO of Mesophotonics. And the new facility
ensures all organisations can now access this exciting new technology
quickly and easily.
Klarite has been designed for use with existing Raman instruments
and its high sensitivity means users can get meaningful, repeatable
results even with lower cost instrumentation. As a result, SERS research
has now become an affordable analytical process for both small and